<?xml version="1.0" encoding="UTF-8"?>
<p>Breast cancer is the most frequently diagnosed cancer in women and is one of the leading causes of cancer death for women. Worldwide, over 1.3 million cases of invasive breast cancer are diagnosed and more than 450,000 women die from breast cancer annually [
 <xref rid="B1-pharmaceuticals-13-00464" ref-type="bibr">1</xref>,
 <xref rid="B2-pharmaceuticals-13-00464" ref-type="bibr">2</xref>]. Breast cancer is a heterogeneous disease with distinct pathological entities and therefore needs diverse therapeutic interventions. Approximately 10â€“20% of invasive breast cancers are triple-negative breast cancer (TNBC) which is defined as the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor (HER) 2 [
 <xref rid="B3-pharmaceuticals-13-00464" ref-type="bibr">3</xref>]. TNBC is associated with poor prognosis, and the survival after metastasis is worse compared to other subtypes [
 <xref rid="B3-pharmaceuticals-13-00464" ref-type="bibr">3</xref>,
 <xref rid="B4-pharmaceuticals-13-00464" ref-type="bibr">4</xref>]. Unfortunately, due to lack of targeted therapy, radiotherapy and chemotherapy remain the only recommended option for TNBC [
 <xref rid="B3-pharmaceuticals-13-00464" ref-type="bibr">3</xref>,
 <xref rid="B5-pharmaceuticals-13-00464" ref-type="bibr">5</xref>,
 <xref rid="B6-pharmaceuticals-13-00464" ref-type="bibr">6</xref>]. Therefore, it is urgent to develop new alternative therapies for TNBC.
</p>
